At a lower dose of 0.2 μg/ml that has been effective against AML progenitors, however, healthy progenitors were only slightly affected by 20D9h3-DUBA (reduction to 74.5% ± 29.4% of control). The gene discussed is OTUD5; the disease is acute myeloid leukemia.